Data Support Increased Subcutaneous Rituximab Use in Non-Hodgkin Lymphoma
Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups
Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.
FDA Approves Bortezomib Injection in Multiple Myeloma/MCL
A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.
Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements
Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.
TLX101/EBRT Shows Preliminary Tolerability, Efficacy in Glioblastoma
Phase 1 data may warrant further investigation of TLX101 plus external beam radiation therapy for patients with recurrent glioblastoma.
IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma
Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.
